← Leaderboards
Jessica Chubak
Kaiser Foundation Health Plan Of Washington
$9,869,663
Attributed
$27,205,505
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,599,012 · 14
By mechanism
UM1$16,625,309 · 2
P01$11,661,455 · 2
R01$4,881,985 · 2
U54$4,728,985 · 2
UH3$1,732,402 · 1
UG3$900,443 · 1
Top collaborators
- Erin Elizabeth Hahn7 shared
- Theresa H M Keegan7 shared
- Lawrence H Kushi7 shared
- Hazel B Nichols7 shared
- Douglas Allen Corley6 shared
- Ruth D Etzioni6 shared
- Ethan A Halm6 shared
- Bin Huang6 shared
Most similar at Kaiser Foundation Health Plan Of Washington
Same institution · by research overlap
- Karen J Wernli$11,067,858
- Aruna Kamineni$6,497,350
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDiagnosisProviderMedicalLinkCancer TherapyColorectalSurveysColorectal CancerEvidence BaseResearch PersonnelCancer SurvivorUnited StatesCaringHealthcareIncidenceBaseInsuranceMultidisciplinaryAgedCancer DiagnosisFollow-UpRecommendationCohort
Grant awards (51)
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$1,473,690
P01 · FY2025 · CA
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$154,093
P01 · FY2025 · CA
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$1,528,781
P01 · FY2024 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$617,580
R01 · FY2024 · CA
Core C: Survey Shared Resource Core$155,478
P01 · FY2024 · CA · contact PI
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$1,167,073
P01 · FY2023 · CA
Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS)$986,593
UM1 · FY2023 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$589,573
R01 · FY2023 · CA
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$564,678
UM1 · FY2023 · CA
Core C: Survey Shared Resource Core$158,749
P01 · FY2023 · CA · contact PI
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$2,977,848
UM1 · FY2022 · CA
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$1,696,125
P01 · FY2022 · CA
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$567,732
UH3 · FY2022 · CA
Core C: Survey Shared Resource Core$304,799
P01 · FY2022 · CA · contact PI
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$180,606
R01 · FY2022 · CA
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$2,565,829
UM1 · FY2021 · CA
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$2,106,400
P01 · FY2021 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$689,634
R01 · FY2021 · CA
Core C: Survey Shared Resource Core$411,164
P01 · FY2021 · CA · contact PI
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$380,204
UH3 · FY2021 · CA
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$193,880
UH3 · FY2021 · CA
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$3,149,821
UM1 · FY2020 · CA
Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers$2,147,232
P01 · FY2020 · CA
Leveraging machine learning to improve risk prediction for chemotherapy induced neuropathy$663,447
R01 · FY2020 · CA
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$590,586
UH3 · FY2020 · CA
Core C: Survey Shared Resource Core$357,871
P01 · FY2020 · CA · contact PI
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$3,116,337
UM1 · FY2019 · CA
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)$3,264,203
UM1 · FY2018 · CA
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$415,381
UG3 · FY2018 · CA
Psychological benefits and potential pathogen transmission in hospitalized pediatric oncology patients receiving therapy dog visits: a randomized controlled trial$233,358
R21 · FY2018 · HD · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$664,689
U54 · FY2017 · CA · contact PI
ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement$485,062
UG3 · FY2017 · CA
Psychological benefits and potential pathogen transmission in hospitalized pediatric oncology patients receiving therapy dog visits: a randomized controlled trial$210,713
R21 · FY2017 · HD · contact PI
Commonly Used Medications and Risk of Colorectal Cancer Recurrence$437,262
R01 · FY2016 · CA · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$1,069,351
U54 · FY2015 · CA · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$649,872
U54 · FY2015 · CA · contact PI
Commonly Used Medications and Risk of Colorectal Cancer Recurrence$540,796
R01 · FY2015 · CA · contact PI
Personalizing colorectal cancer screening and surveillance$154,900
U54 · FY2015 · CA · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$7,965
U54 · FY2015 · CA · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$1,078,364
U54 · FY2014 · CA · contact PI
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)$649,872
U54 · FY2014 · CA · contact PI
Commonly Used Medications and Risk of Colorectal Cancer Recurrence$562,249
R01 · FY2014 · CA · contact PI
Personalizing colorectal cancer screening and surveillance$151,054
U54 · FY2014 · CA · contact PI
Developing trials of animal-assisted activities for youth with cancer$79,227
R03 · FY2014 · CA · contact PI
Commonly Used Medications and Risk of Colorectal Cancer Recurrence$600,838
R01 · FY2013 · CA · contact PI
Personalizing colorectal cancer screening and surveillance$164,319
U54 · FY2013 · CA · contact PI
Developing trials of animal-assisted activities for youth with cancer$87,696
R03 · FY2013 · CA · contact PI
Personalizing colorectal cancer screening and surveillance$138,599
U54 · FY2012 · CA · contact PI
Algorithms to Identify Second Breast Cancer Events from Electronic Data$161,213
R21 · FY2011 · CA · contact PI
Risk of Non-Hodgkin's Lymphoma in Relation to Tricyclic Antidepressant Use$80,000
R03 · FY2011 · CA · contact PI
Algorithms to Identify Second Breast Cancer Events from Electronic Data$216,226
R21 · FY2010 · CA · contact PI